Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed harmful genetic mutation in one of the following genes: BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, or ATM
- People who are over 18 years of age
- People who have been diagnosed with prostate cancer and are at a point where imaging to check the stage of their cancer is medically appropriate, which includes one of three situations: a new prostate cancer diagnosis; a rising PSA level after having had surgery or radiotherapy more than 6 months ago, while not currently receiving hormone therapy or chemotherapy; or people on active surveillance whose PSA level is doubling every 6 months or less
Who may not be able to join:
- People who have been diagnosed with another cancer (other than certain skin cancers) within the past five years
- People who are already known to have prostate cancer that has spread, whether to nearby areas or to distant parts of the body
- People who have received any cancer treatment within the last six months
- People who are currently taking part in another clinical trial involving an experimental drug
- People who are currently taking steroid medications
- People with a known history of certain inflammatory or infectious conditions, such as sarcoidosis, tuberculosis, or inflammatory bowel disease
- People for whom an MRI scan would not be safe, such as those with a pacemaker, certain surgical clips in the brain, or severe claustrophobia (confirm with trial site for the full MRI safety checklist)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rosalind A Eeles, FRCP FRCR, Institute of Cancer Research and Royal Marsden Hospital
Phone: +44 208 722 4483
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1. Sensitivity of FCH-PET-CT scan
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.